RNS Number : 4620X
Cambridge Cognition Holdings PLC
01 September 2025
 

 

01 September 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Investor Presentation via Investor Meet Company

 

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce that Rob Baker (Group Chief Operating Officer and Senior Executive Director) and Ronald Openshaw (Chief Financial Officer and Head of Corporate Development) will provide a live presentation relating to the Interim Results via Investor Meet Company on 03 September 2025, 11:00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 02 September 2025, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Cambridge Cognition Holdings plc via:

https://www.investormeetcompany.com/cambridge-cognition-holdings-plc/register-investor

Investors who already follow Cambridge Cognition Holdings plc on the Investor Meet Company platform will automatically be invited.

 

Enquiries:

 

Cambridge Cognition Holdings plc

Rob Baker, Group Chief Operating Officer and

Senior Executive Director

 

 

Tel: 012 2381 0700

press@camcog.com

Panmure Liberum Limited (NOMAD and Joint Broker)

Will Goode / Freddy Crossley / Mark Rogers

Rupert Dearden

 

 

Tel: 020 7886 2968

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / Amber Higgs

 

 

Tel: 020 3903 7715


 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.  The Company has identified four market sectors:

·    Clinical Studies for new pharmaceuticals;

·    Academic Research for scientists to understand CNS disorders;

·    Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

·    Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

 

END

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGCGDCIUGDGUB